Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease.

@article{Kosler2017LacticAB,
  title={Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease.},
  author={Stasa Kosler and B. Strukelj and Ale{\vs} Berlec},
  journal={Current pharmaceutical biotechnology},
  year={2017},
  volume={18 4},
  pages={318-326}
}
BACKGROUND Neutralization of proinflammatory cytokines is an established strategy in the treatment of inflammatory bowel disease (IBD). Systemic anti-TNFα antibodies have been used in the clinics for several years, while anti-IL-17/IL-23 antibodies have been less successful so far. We report the development of safe lactic acid bacterium Lb. salivarius with the ability to simultaneously bind IL-17A, IL-23 and TNFα that could be administered orally for the treatment of IBD. METHOD Three… CONTINUE READING